ARTICLE | Finance
Burgeoning bellwethers
26th annual Buyside View sees biotech investors eyeing small- and mid-caps in 2018
January 6, 2018 12:38 AM UTC
The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one.
Buysiders spent most of 2017 focusing to a large degree on the big caps, which had been riding clinical data and commercial launches to new heights. Biotechs valued at $10 billion and up had a median gain in value of 16.1% through 3Q17, adding $248.4 billion in market cap in the first nine months of the year. ...
BCIQ Company Profiles
BCIQ Target Profiles